Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Urovant Sciences (UROV)

Urovant Sciences Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:UROV
DateTimeSourceHeadlineSymbolCompany
13/04/202217:02Business WireUrovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual MeetingNASDAQ:UROVUrovant Sciences Ltd
07/03/202216:56Business WireUrovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902NASDAQ:UROVUrovant Sciences Ltd
20/12/202117:11Business WireUrovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mgNASDAQ:UROVUrovant Sciences Ltd
08/11/202113:00Business WireUrovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder PatientsNASDAQ:UROVUrovant Sciences Ltd
01/04/202111:14Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:UROVUrovant Sciences Ltd
31/03/202117:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202117:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202117:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202117:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202117:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202117:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202117:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202117:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202117:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202117:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
30/03/202117:13Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:UROVUrovant Sciences Ltd
29/03/202120:13Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:UROVUrovant Sciences Ltd
29/03/202120:09Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:UROVUrovant Sciences Ltd
29/03/202120:06Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:UROVUrovant Sciences Ltd
29/03/202120:04Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:UROVUrovant Sciences Ltd
29/03/202113:44Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:UROVUrovant Sciences Ltd
29/03/202113:36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:UROVUrovant Sciences Ltd
24/03/202120:30Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:UROVUrovant Sciences Ltd
19/02/202111:11Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:UROVUrovant Sciences Ltd
19/02/202111:05Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:UROVUrovant Sciences Ltd
16/02/202120:38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:UROVUrovant Sciences Ltd
12/02/202122:43Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:UROVUrovant Sciences Ltd
12/02/202121:13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:UROVUrovant Sciences Ltd
12/02/202121:05Business WireUrovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 ResultsNASDAQ:UROVUrovant Sciences Ltd
11/02/202113:00Business WireUrovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data & Safety Mon...NASDAQ:UROVUrovant Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:UROV

Your Recent History

Delayed Upgrade Clock